Evaluating recovery of continence and sexual function after prostate cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The CONTROL 4 LIFE study focuses on understanding the recovery of continence, sexual function, and overall health in men who have undergone prostate cancer surgery. Participants will receive resources from Alberta Health Services, including pelvic floor exercises and a hybrid rehabilitation program that combines in-person and virtual support. The study aims to assess the feasibility and effectiveness of this program on urinary continence and other health outcomes compared to usual care. By evaluating physical activity, fitness, and quality of life, the study seeks to provide insights into the recovery timeline after prostatectomy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* have a diagnosis of prostate cancer (stage I to IV);
* be scheduled for a prostatectomy surgery (any surgical approach);
* have no restriction to participate in at least mild levels of physical activity, as confirmed by the Physical Activity Readiness Questionnaire (PAR-Q+);
* speak and understand English.
* adult: 18 years of age or older
* optional exercise component: willing and able to commit to the 12-week intervention

Exclusion Criteria:

* have any medical conditions that may interfere with continence (i.e. neurological diseases);
* have any contraindications to exercise testing or training;
* have recent (\>6 months) modifications to any medication aiming to reduce urinary incontinence (i.e. Myrbetric);
* do not have regular access to the internet and a smart device or a computer at home/ at their community center;
* are already receiving a pelvic floor exercise program through a pelvic floor physical therapist from their community.

Where it's running

• University of Alberta
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Principal investigator: Nathan Hoy, MD — University of Alberta
• Study coordinator: Margaret L McNeely
• Email: mmcneely@ualberta.ca
• Phone: 780-492-6007

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.